常规分子诊断检测结核分枝杆菌利福平异质性耐药的效能评估
该研究以CFU计数和靶向深度测序(Deeplex-MycTB)为参考,评估四种常规快速诊断技术(XpertMTB/RIF、XpertMTB/RIF Ultra、GenoTypeMTBDRplusv2.0和GenoscholarNTM+MDRTBII)检测利福平异质性耐药的最低检测限(LOD)。结果显示不同技术及不同突变位点的LOD差异显著,经典Xpert和Ultra报告异质性耐药为利福平耐药,而Ultra可能通过熔解探针混合模式提示异质性耐药。
要点
- 经典Xpert和Ultra检测利福平异质性耐药的LOD最高(20%–80%),易将异质性耐药报告为耐药。
- GenoscholarNTM+MDRTBII对异质性耐药的LOD最低(1%–10%),GenoTypeMTBDRplusv2.0为5%–10%。
- Ultra可能通过野生型和突变型熔解探针熔解峰温度的「混合模式」提示异质性耐药。
核心结论
- 不同常规分子诊断技术检测利福平异质性耐药的LOD差异大,经典Xpert和Ultra报告耐药阈值最高,可能导致表型与基因型利福平耐药结果不一致。
研究设计与样本
- 选取1株利福平敏感株和4株利福平耐药株(突变D435V、H445D、H445Y、S450L),按不同比例混合(三重复),用四种RDT检测,以CFU计数和Deeplex-MycTB验证LOD。
主要发现
- Deeplex-MycTB验证的LOD范围:XpertMTB/RIF为20%–80%,Xpert Ultra为20%–70%,GenoTypeMTBDRplusv2.0为5%–10%,GenoscholarNTM+MDRTBII为1%–10%(不同突变间)。
- Deeplex-MycTB、GenoTypeMTBDRplusv2.0和GenoscholarNTM+MDRTBII可对最常见突变提供利福平异质性耐药的明确信息。
- 经典Xpert和Ultra将利福平异质性耐药报告为利福平耐药,Ultra可能通过「混合模式」提示异质性耐药。
关键数值与推荐
- 表型药物敏感性试验比例法的利福平异质性耐药LOD为1%。
- XpertMTB/RIF的LOD为20%–80%,Xpert Ultra为20%–70%,GenoTypeMTBDRplusv2.0为5%–10%,GenoscholarNTM+MDRTBII为1%–10%。
临床怎么用
- 检验科应了解所用分子诊断技术检测利福平异质性耐药的LOD差异,经典Xpert和Ultra高LOD可能导致表型与基因型耐药结果不一致。
局限性
- 仅评估了四种RDT和四种特定突变(D435V、H445D、H445Y、S450L),未涵盖其他突变类型或技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rifampin heteroresistance-where rifampin-resistant and -susceptible tuberculosis (TB) bacilli coexist-may result in failed standard TB treatment and potential spread of rifampin-resistant strains. The detection of rifampin heteroresistance in routine rapid diagnostic tests (RDTs) allows for patients to receive prompt and effective multidrug-resistant-TB treatment and may improve rifampin-resistant TB control. The limit of detection (LOD) of rifampin heteroresistance for phenotypic drug susceptibility testing by the proportion method is 1% and, yet, is insufficiently documented for RDTs. We, therefore, aimed to determine, for the four RDTs (XpertMTB/RIF, XpertMTB/RIF Ultra, GenoTypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII), the LOD per probe and mutation, validated by CFU counting and targeted deep sequencing (Deeplex-MycTB). We selected one rifampin-susceptible and four rifampin-resistant strains, with mutations D435V, H445D, H445Y, and S450L, respectively, mixed them in various proportions in triplicate, tested them with each RDT, and determined the LODs per mutation type. Deeplex-MycTB revealed concordant proportions of the minority resistant variants in the mixtures. The Deeplex-MycTB-validated LODs ranged from 20% to 80% for XpertMTB/RIF, 20% to 70% for Xpert Ultra, 5% to 10% for GenoTypeMTBDRplusv2.0, and 1% to 10% for GenoscholarNTM+MDRTBII for the different mutations. Deeplex-MycTB, GenoTypeMTBDRplusv2.0, and GenoscholarNTM+MDRTBII provide explicit information on rifampin heteroresistance for the most frequently detected mutations. Classic Xpert and Ultra report rifampin heteroresistance as rifampin resistance, while Ultra may denote rifampin heteroresistance through "mixed patterns" of wild-type and mutant melt probe, melt peak temperatures. Overall, our findings inform end users that the threshold for reporting resistance in the case of rifampin heteroresistance is the highest for Classic Xpert and Ultra to resolve phenotypic and genotypic discordant rifampin-resistant TB results.
引用
- Ng KCS, Supply P, Cobelens FGJ, et al. How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis? J Clin Microbiol. 2019. PMID: 31413081. doi:10.1128/JCM.00717-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。